JBL
JA
EN
  • About Us
    • Vision, Values & Promise
    • Company Overview
    • Leadership Team
    • Our People
    • Our Facilities
    • Contact Us
  • Services
    • Integrated Drug Discovery
      • Target Identification
      • Target Validation
      • HIT Identification
      • HIT to Lead
      • Lead Optimization
      • Candidate Selection
    • Chemistry
      • Synthetic Chemistry
      • Medicinal Chemistry
      • Analytical Chemistry
      • Computational Chemistry
      • Specialised Chemistry-COE
      • Oligonucleotide Offerings
    • Protein Sciences and Crystallography
      • Custom Protein Production
      • SPR
      • Crystallography
      • SBDD
    • Assay Biology
      • In-Vitro Biology
      • Target Validation
      • Bio-Chemical Assay, D&S
      • Cell Based Assay, D&S
      • Mode of Action Studies
      • Biomarker Evaluation
    • DMPK
      • Physicochemical Properties
      • In-Vitro ADME
      • In-Vivo Pharmacokinetics
      • Drug Interactions
      • Metabolite Identification
      • Bioanalysis
      • Large Molecule Bioanalysis
    • Computational Chemistry (CADD)
      • Virtual Screening
      • LBDD
      • Insilico FBDD
      • Chemoinformatics
    • Pharmacology
      • Oncology Animal Models
      • Inflammation Animal Models
      • Pain and Neuroscience Animal Models
      • Diabetes & Metabolic Disorders Animal Models
    • Toxicology
      • GLP & Non GLP Studies
      • Acute Toxicity
      • Subchronic Toxicity
      • Genetic Toxicity
      • Safety Pharmacology
      • Toxicokinetics
    • CDMO
      • Process R&D Services
      • Analytical Development
      • Process Safety Studies
      • Polystate Capabilities
      • Technology Transfer
      • Early to Late Phase Supplies
      • GLP, Non-GMP and GMP Mfg.
    • Biologics
      • Recombinant Protein Production
      • ADC Capabilities
      • API
        • API Capabilities
    • For more information reach us at: bd@jubilantbiosys.com
  • Target Approaches
    • Kinases
    • Non-Kinase Enzymes
    • GPCRs & Ion Channels
    • Transcription Factors
    • Immune Regulators
    • Target Protein Degradation
    • RNA Small Molecule Drugs
  • Resources
    • News
    • Press Releases
    • Events
    • Publications
    • Articles
    • Whitepapers
    • Scientific Posters
    • Brochures
    • Webinars
    • Customer Testimonials
    • Annual Return
  • Careers

A CRO that supports drug discovery ideas and passion – Jubilant Biosys

Posted on June 17, 2020May 7, 2026 by ddAdmin

BIO Impact Interview June 2020 with Dr Takeshi Yura

Posted in Publications

Get in touch

For Business Queries
bd@jubilantbiosys.com
For Career Related Queries
careers@jubilantbiosys.com

Services

  • Integrated Drug Discovery
  • Chemistry
  • Protein Sciences and Crystallography
  • Assay Biology
  • DMPK
  • Computational Chemistry (CADD)
  • Pharmacology
  • Toxicology
  • CDMO

Our Locations

    R&D Centers
  • Noida, India
  • Greater Noida, India
  • Bengaluru, India
  • Saint Julien, France
Manufacturing Plant
  • Nanjangud, India

Company

  • Facilities
  • Contact
  • News

Our Commitment

  • Corporate Governance
  • Quality & IP
  • Policies

Careers

  • Returning Indian Talent
  • Recruitment Fraud Advisory
  • Group Ombudsperson

© 2026 Jubilant Biosys Limited A Jubilant Pharmova Limited Company

  • Policies
  • Jubilant Bhartia Group
  • Sitemap
  • Disclaimer
  • Payment

Request For Information

We appreciate all business enquiries, If you'd like our Business Development team to contact you, please complete this form.

    Jubilant Biosys respects your privacy. We collect and process your personal data for specified purposes, which may include providing services you request and, where applicable, sending marketing communications. Please review our Privacy Notice to understand how your data is used.

    We use cookies to recognize your repeat visits and preferences, as well as to measure the effectiveness of campaigns and analyse traffic. If you continue to use this site, we will assume your acceptance.

    PRIVACY POLICY